In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Pfizer Inc’s stock clocked out at $25.21, up 0.08% from its previous closing price of $25.19. In other words, the price has increased by $0.08 from its previous closing price. On the day, 37.77 million shares were traded. PFE stock price reached its highest trading level at $25.4 during the session, while it also had its lowest trading level at $25.13.
Ratios:
To gain a deeper understanding of PFE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.62.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $30.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $24.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $24 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Dolsten Mikael bought 59,781 shares for $23.09 per share.
Dolsten Mikael bought 55,000 shares of PFE for $1,312,736 on May 05 ’25. On Mar 04 ’25, another insider, DAMICO JENNIFER B., who serves as the SVP & Controller of the company, sold 2,500 shares for $25.93 each. As a result, the insider received 64,825 and left with 11,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PFE now has a Market Capitalization of 143336685568 and an Enterprise Value of 190583685120. As of this moment, Pfizer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.69, and their Forward P/E ratio for the next fiscal year is 8.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.28 while its Price-to-Book (P/B) ratio in mrq is 1.54. Its current Enterprise Value per Revenue stands at 3.035 whereas that against EBITDA is 7.792.
Stock Price History:
The Beta on a monthly basis for PFE is 0.43, which has changed by -0.057965577 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, PFE has reached a high of $27.69, while it has fallen to a 52-week low of $20.92. The 50-Day Moving Average of the stock is 0.52%, while the 200-Day Moving Average is calculated to be 2.84%.
Shares Statistics:
It appears that PFE traded 69.29M shares on average per day over the past three months and 58743750 shares per day over the past ten days. A total of 5.69B shares are outstanding, with a floating share count of 5.68B. Insiders hold about 0.09% of the company’s shares, while institutions hold 66.89% stake in the company. Shares short for PFE as of 1764288000 were 139072627 with a Short Ratio of 2.01, compared to 1761868800 on 126587750. Therefore, it implies a Short% of Shares Outstanding of 139072627 and a Short% of Float of 2.4500001.
Dividends & Splits
With its trailing 12-month dividend rate of 1.7, PFE has a forward annual dividend rate of 1.72. Against a Trailing Annual Dividend Yield of 0.0674871. The stock’s 5-year Average Dividend Yield is 4.82. The current Payout Ratio is 120.11% for PFE, which recently paid a dividend on 2025-11-07 with an ex-dividend date of 2026-01-23. Stock splits for the company last occurred on 2020-11-17 when the company split stock in a 1054:1000 ratio.
Earnings Estimates
Investors are keenly observing as 16.0 analysts analyze and rate. The current performance of Pfizer Inc (PFE) in the stock market.The consensus estimate for the next quarter is $0.76, with high estimates of $0.92 and low estimates of $0.67.
Analysts are recommending an EPS of between $3.24 and $3.0 for the fiscal current year, implying an average EPS of $3.12. EPS for the following year is $3.0, with 25.0 analysts recommending between $3.3 and $2.8.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $16.95B. It ranges from a high estimate of $17.7B to a low estimate of $16.13B. As of. The current estimate, Pfizer Inc’s year-ago sales were $17.76BFor the next quarter, 15 analysts are estimating revenue of $14.02B. There is a high estimate of $14.52B for the next quarter, whereas the lowest estimate is $13.6B.
A total of 19 analysts have provided revenue estimates for PFE’s current fiscal year. The highest revenue estimate was $62.7B, while the lowest revenue estimate was $61.15B, resulting in an average revenue estimate of $62.01B. In the same quarter a year ago, actual revenue was $63.63BBased on 21 analysts’ estimates, the company’s revenue will be $61.2B in the next fiscal year. The high estimate is $62.79B and the low estimate is $59.86B.
